BLUFFDALE, Utah, May 12, 2022 — Med 7, LLC (www.med7cbd.com) and HempCo, Inc. announce the completion and publication of the first prospective human clinical study to assess the effects of a CBD-rich full-spectrum hemp oil in patients with COVID-19 (SARS-CoV-2). The study used Med 7®, a full-spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81™. “We are extremely fortunate to publish the first prospective, double-blind, placebo-controlled human clinical trial with a CBD-rich full-spectrum hemp oil in patients who test positive for COVID,” said Matt Smith, CEO of Med 7. “We were in the initial stages of our study of Med 7 in 150 patients with Type 2 Diabetes, when COVID hit our study population hard. Rather than discontinuing the study, we decided to keep going to see if Med 7 had any impact on those who tested positive for COVID. This was in early 2020 when no one knew much about the physiological effects of COVID, so we were not even sure at first what to study other than mortality and hospitalization rates. Since we had seen significantly positive effects of Hempzorb81™ on cytokines (inflammatory markers) in a previous safety and efficacy study, we decided to look at those markers again, as well as white blood cell counts, to see what was going on in the immune system,” explained Smith. [Read more…] about MED 7 LLC AND HEMPCO IC. ANNOUNCE THE PUBLICATION OF THE FIRST PROSPECTIVE HUMAN CLINICAL TRIAL USING A CBD-RICH FULL-SPECTRUM HEMP OIL IN PATIENTS WITH COVID-19
BLUFFDALE, Utah, Oct. 1, 2021 /PRNewswire/ — Med 7, LLC (www.Med 7cbd.com) and HempCo, Inc. announce the completion of a human clinical study to assess the effects of Med 7 on sleep. Med 7 is a full spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81. “Over 30 million Americans suffer from sleep issues affecting work productivity and quality of life” said Matt Smith, CEO of Med 7. “In our first Hempzorb81 safety and efficacy study, 91% of the patients on Med 7 reported better sleep and more active dreaming. We wanted to do a deep dive and see the effects of Hempzorb81 on sleep cycles and other health measurements.” This study was done with support of the National Institutes of Health (NIH) as part of their small business grant program.[Read more…] about Med 7 LLC, announces the completion of a Sleep Study using Hempzorb81™ Full Spectrum Hemp Oil
BLUFFDALE, Utah, April 29, 2021 /CNW/ — Med7, LLC (www.Med7cbd.com) and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb® technology, now trademarked as Hempzorb81TM. “This study will provide our customers and providers with evidence based products not seen to this point in the Industrial Hemp and CBD market place,” said Matt Smith, CEO of Med7. This study was done with support from the National Institutes of Health (NIH) as part of their small business grant program.[Read more…] about Med 7 llc, announce the completion of a safety and efficacy study using hempzorb81™ full spectrum oil in patients with type ii diabetes
LAS VEGAS, NV – PurHealthRX® announced the completion of the first major clinical study looking at the anti-aging effects and safety of full spectrum hemp CBD oil in human subjects. The study was completed with support from the National Institute of Health (NIH).
The randomized placebo-controlled study on 150 patients showed that full spectrum hemp CBD oil had a significant effect on a multitude of anti-aging related factors.
The study looked at inflammation markers, cardiovascular and metabolism indicators while also tracking anxiety and sleep.
“We are very pleased that our Purzorb® formulation of full spectrum hemp CBD oil showed such a strong effect in these anti-aging factors,” said Matt Smith, CEO.
“Inflammation and cardiovascular problems are part of the aging process. By showing a significant effect on so many of these factors, there is strong evidence that the endocannabinoid system plays a significant role in the anti-aging process,” Smith said.
According to Smith, this is the first non-pharmaceutical study demonstrating both the safety and efficacy of naturally occurring cannabinoids such as CBD.
PurHealthRX® scientists have been working on methods to deliver naturally occurring cannabinoids since 2014. “Working with industrial hemp since the 2014 Farm Bill passed has given us a great understanding of the problems that face this market,” Smith explained.
“The inconsistencies, impurities and no standardization, coupled with a lack of clinical data, has created a lot of confusion with consumers who could really benefit from CBD products,” Smith said.
The study looked at inflammatory markers such as Tumor Necrosis Factor Alpha, Interleukin 6, C-Reactive Protein and NF-κB. Metabolism and cardiovascular indicators such as HA1c, LDL/HDL and Homocysteine levels were also measured. One of the significant findings was that the HA1c levels dropped by an average of almost one point in the test subjects.
PurHealthRX® is a technology-driven health and wellness company that manufactures, distributes and sells full spectrum hemp CBD oil products using Purzorb®, a proprietary technology that mimics the body’s natural process of absorption by converting oil-based nutrients into water-soluble products. Purzorb® products are sold under the Med 7® and Pur 7® brands, and marketed as Biosorb™ in products sold through Q Sciences.
601 E. Charleston Blvd Suite 100
Las Vegas, NV 89104